Cyprotex offer a number of unique technologies either developed in-house or through our collaborators/partners.
Synchronously beating iPS cell derived cardiomyocytes are monitored by high throughput microelectrode array (MEA) to measure whole cell electrophysiology and an ECG-like response. This technology provides a unique in vitro system for preclinical drug discovery, cardiotoxicity assessment and disease modeling.
Primary cortical neurons are monitored by high throughput microelectrode array (MEA). The cells recapitulate many features of neurons in vivo, and enable assessment of spiking rate, burst characteristics and synchrony. This technology provides a unique in vitro system for preclinical drug discovery, neurotoxicity assessment and disease modeling.
An extensive panel of toxicological endpoints are assessed in multiple cell types and at multiple time points using high content screening (HCS). By combining these endpoints with exposure levels (measured Cmax or predicted Cmax using Cloe® PK), the system delivers a sensitive and specific prediction of DILI (drug-induced liver injury).
Compared to 2D cellular models, 3D microtissues more closely mimic native tissue and allow multiple dosing over an extended exposure period. Cyprotex offer both 3D liver and cardiac tissue models for assessing drug metabolism and drug-induced toxicity.